ATE395072T1 - Tnf-peptide zur behandlung von ödemen - Google Patents

Tnf-peptide zur behandlung von ödemen

Info

Publication number
ATE395072T1
ATE395072T1 AT02077274T AT02077274T ATE395072T1 AT E395072 T1 ATE395072 T1 AT E395072T1 AT 02077274 T AT02077274 T AT 02077274T AT 02077274 T AT02077274 T AT 02077274T AT E395072 T1 ATE395072 T1 AT E395072T1
Authority
AT
Austria
Prior art keywords
alpha
present
oedema
edema
treatment
Prior art date
Application number
AT02077274T
Other languages
German (de)
English (en)
Inventor
Baetselier Patrick De
Alain Bloc
Rudolf Lucas
Lucie Fransen
Jerome Pugin
Original Assignee
Rudolf Lucas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rudolf Lucas filed Critical Rudolf Lucas
Application granted granted Critical
Publication of ATE395072T1 publication Critical patent/ATE395072T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02077274T 1998-08-14 1999-08-10 Tnf-peptide zur behandlung von ödemen ATE395072T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
ATE395072T1 true ATE395072T1 (de) 2008-05-15

Family

ID=27239778

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02077274T ATE395072T1 (de) 1998-08-14 1999-08-10 Tnf-peptide zur behandlung von ödemen
AT02077256T ATE374039T1 (de) 1998-08-14 1999-08-10 Tnf-peptide und deren verwendung zur behandlung von ödemen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02077256T ATE374039T1 (de) 1998-08-14 1999-08-10 Tnf-peptide und deren verwendung zur behandlung von ödemen

Country Status (20)

Country Link
US (2) US20030105021A1 (enExample)
EP (3) EP1105152A1 (enExample)
JP (1) JP4542266B2 (enExample)
CN (1) CN1181886C (enExample)
AT (2) ATE395072T1 (enExample)
AU (1) AU764992B2 (enExample)
BR (1) BR9912899A (enExample)
CA (1) CA2334941C (enExample)
CZ (1) CZ302862B6 (enExample)
DE (2) DE69937206T2 (enExample)
DK (1) DK1264599T3 (enExample)
ES (1) ES2296872T3 (enExample)
HU (1) HU227661B1 (enExample)
IL (2) IL141064A0 (enExample)
NZ (1) NZ509604A (enExample)
PL (1) PL203706B1 (enExample)
PT (1) PT1264599E (enExample)
TR (1) TR200100338T2 (enExample)
WO (1) WO2000009149A1 (enExample)
ZA (1) ZA200100656B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302862B6 (cs) 1998-08-14 2011-12-21 Lécivo na lécení otoku
JP5108515B2 (ja) * 2004-08-06 2012-12-26 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺サーファクタント及びtnf由来ペプチドを含有する組成物
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PL2397151T3 (pl) * 2010-06-21 2015-10-30 Apeptico Forschung & Entwicklung Gmbh Leczenie powikłań naczyniowych cukrzycy
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
ES2813379T3 (es) * 2013-04-23 2021-03-23 Apeptico Forschung & Entwicklung Gmbh Tratamiento extracorporal del pulmón con un péptido cíclico de formula x1-gqretpegaeakpwy-x2
ES2665180T3 (es) 2014-03-18 2018-04-24 Apeptico Forschung Und Entwicklung Gmbh Medicamento de péptido en forma de polvo seco
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
CZ302862B6 (cs) 1998-08-14 2011-12-21 Lécivo na lécení otoku

Also Published As

Publication number Publication date
HUP0103117A2 (hu) 2001-12-28
CN1312724A (zh) 2001-09-12
CA2334941C (en) 2011-08-09
DE69938743D1 (de) 2008-06-26
CA2334941A1 (en) 2000-02-24
DK1264599T3 (da) 2008-02-04
CN1181886C (zh) 2004-12-29
EP1264599B1 (en) 2007-09-26
US20030105021A1 (en) 2003-06-05
WO2000009149A1 (en) 2000-02-24
NZ509604A (en) 2003-05-30
EP1105152A1 (en) 2001-06-13
DE69937206T2 (de) 2008-06-19
HUP0103117A3 (en) 2004-03-01
JP4542266B2 (ja) 2010-09-08
PL345997A1 (en) 2002-01-14
US20030185791A1 (en) 2003-10-02
US7258861B2 (en) 2007-08-21
PL203706B1 (pl) 2009-11-30
ES2296872T3 (es) 2008-05-01
HK1051805A1 (en) 2003-08-22
JP2002522508A (ja) 2002-07-23
IL141064A0 (en) 2002-02-10
AU764992B2 (en) 2003-09-04
CZ2001538A3 (cs) 2001-08-15
ATE374039T1 (de) 2007-10-15
PT1264599E (pt) 2008-01-07
AU5620999A (en) 2000-03-06
HU227661B1 (hu) 2011-10-28
ZA200100656B (en) 2005-06-29
DE69937206D1 (de) 2007-11-08
EP1264599A1 (en) 2002-12-11
BR9912899A (pt) 2001-05-08
EP1247531A3 (en) 2002-12-18
EP1247531B1 (en) 2008-05-14
CZ302862B6 (cs) 2011-12-21
EP1247531A2 (en) 2002-10-09
TR200100338T2 (tr) 2001-12-21
IL141064A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
DE69938743D1 (de) TNF-Peptide zur Behandlung von Ödemen
EA200400632A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
WO2003008443A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE69922819D1 (de) Methode zur prävention und behandlung von dehnungsstreifen (striae distensae) und deren verwendung in dermatologie
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
DK0397420T3 (da) Enzymatisk fjernelse af en aminoterminal proteinsekvens
NZ333609A (en) Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells
DE69904511D1 (de) Proteinmaterial mit verlangsamtem verdaungsablauf und deren verwendung
DE69229050D1 (de) Verwendung von Papillomavirusprotein L2 zur therapeutischen Behandlung von durch Papillomavirus hervorgerufenen Tumoren oder oder anderen krankhaften Veränderungen
DE60217326D1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
DE69329899D1 (de) Behandlung von tropikalischer spastischer Paresis mit Peptide T
DE602004016834D1 (de) Zusammensetzung zur vermeidung und behandlung von cellulitis
ATE310091T1 (de) Carboxypeptidasen aus aspergillus oryzae und diese kodierende nukleinsäuren
DE3786456D1 (de) Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
DE69526972D1 (de) Verwendung von Gabapentin in der Behandlung vonAngst - und Panikstörungen
DE60104695D1 (de) Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz
ATE342352T1 (de) Entwurf und verwendung von verbesserten zink- chelatbildenden peptiden zur regulation von matrix-metalloproteinasen
DE50001730D1 (de) Gemisch zur behandlung von abfallmaterial
DE50006409D1 (de) Injektionslösung enthaltend eine goldverbindung, calendula und belladonna extrakte zur behandlung von arthrosen
DE602006017806D1 (de) Behandlung von neurodegeneration
DE69915852D1 (de) Lhrh-analoga zur behandlung der osteoporose
RU97119664A (ru) Способ получения основы для производства безалкогольных напитков
DE50000562D1 (de) Mittel zur behandlung von pigmentierungsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1247531

Country of ref document: EP

EEIH Change in the person of patent owner